Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Lilly Stops Development of Schizophrenia Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Lilly Stops Development of Schizophrenia Drug

Analysis shows unlikely to meet efficacy endpoint

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly and Co. has stopped clinical studies for pomaglumetad methionil, or mGlu2/3, for the treatment of schizophrenia. The decision follows analysis of two Phase III studies showing that the drug was unlikely to meet its primary efficacy endpoint. The decision was not based on any safety signals.
 
“I’m disappointed in what these results mean for patients with schizophrenia who still are searching for options to treat this terrible illness,” said Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories.  “While there are many challenges in this complex field of research, neuroscience remains a core area of focus at Lilly. Our clinical development pipeline includes nearly a dozen neuroscience molecules being studied to treat illnesses such as depression, bipolar disorder and cognitive impairment associated with schizophrenia.”
 
The decision is expected to result in a third-quarter charge in the range of $25 million to $30 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics